New investor Essex Woodlands Health Ventures led the round, with participation from existing investors Burrill & Company, HealthCare Ventures, Johnson & Johnson Development, Morgenthaler Ventures, Novartis BioVentures and Sofinnova Ventures.
In conjunction with the financing, Jeff Himawan from Essex Woodlands will join Catalyst Biosciences’s board of directors.
Nassim Usman, CEO of Catalyst Biosciences, said: “We are very pleased to have received such strong support from our investors and to add Essex Woodlands to this premier group.
“The financing provides us with several years of funding that will allow us to build our pipeline of Alterase therapeutics including advancing our lead protease, CB 813, an improved Factor VIIa product for the treatment of acute bleeding in hemophiliacs, through Phase I/II proof-of-concept studies in patients.”